Tumor Treatment Field Therapy Bibliography for Contractor Advisory Committee Meeting - JA DME
Tumor Treatment Field Therapy Bibliography for Contractor Advisory Committee Meeting
The following bibliography was provided to the Contractor Advisory Committee (CAC) for their consideration of Tumor Treatment Field Therapy in the treatment of newly diagnosed glioblastoma multiforme.
Submitted by Novocure with Reconsideration Request
Stupp R, Taillibert S, Kanner A, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015;314(23):2535-2543. doi:10.1001/jama.2015.16669
Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318(23):2306. doi:10.1001/jama.2017.18718
Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncology. 2018;4(4):495. doi:10.1001/jamaoncol.2017.5082
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. NCCN Flash Card™. Version 1.2018 March 20, 2018.
Provided by DME MACs
Bhandari M. Comparative Study of Adjuvant Temozolomide six Cycles Versus Extended 12 Cycles in Newly Diagnosed Glioblastoma Multiforme. Journal Of Clinical And Diagnostic Research. 2017. doi:10.7860/JCDR/2017/27611.9945
Cloughesy TF, Lassman AB. NovoTTF: where to go from here? Neuro-Oncology. 2017;19(5):605-608. doi:10.1093/neuonc/nox014
Food and Drug Administration. Summary of Safety and Effectiveness Data. PMA P100034. Novocure TTF-100A. April 8, 2011
Food and Drug Administration. Summary of Safety and Effectiveness Data. PMA P100034/S013. Novocure TTF-100A. October 5, 2015
Food and Drug Administration. Novocure Submission to Neurological Devices Panel. NovoTTF-100A. March 17, 2011.
Kesari S, Ram Z, on behalf of EF-14 Trial Investigators. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. CNS Oncology. 2017;6(3):185-193. doi:
Kirson ED, Dbaly V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proceedings of the National Academy of Sciences. 2007;104(24):10152-10157. doi: 10.1073/pnas.0702916104.
Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of Cancer Cell Replication by Alternating Electric Fields. Cancer Research. 2004;64(9):3288-3295. doi: 10.1158/0008-5472.can-04-0083.
Martínez-Garcia M, Álvarez-Linera J, Carrato C, et al. SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clinical and Translational Oncology. 2018;20(1):22-28. doi:10.1007/s12094-017-1763-6
Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Critical Reviews in Oncology/Hematology. 2017;111:60-65. doi:10.1016/j.critrevonc.2017.01.005
Mittal S, Klinger NV, Michelhaugh SK, Barger GR, Pannullo SC, Juhász C. Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies. Journal of Neurosurgery. February 2018:414-421. doi:10.3171/2016.9.JNS16452
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Version 2.2018 November 26, 2018. Accessed January 3, 2019.
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. NCCN Evidence Blocks™. Version 2.2018 November 26, 2018. Accessed January 3, 2019.
Palmer JD, Bhamidipati D, Mehta M, et al. Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus. Journal of Neuro-Oncology. 2018;140(2):421-426. doi:10.1007/s11060-018-2969-3
Sampson JH. Alternating Electric Fields for the Treatment of Glioblastoma. JAMA. 2015;314(23):2511. doi:10.1001/jama.2015.16701
Sulman EP, Ismaila N, Armstrong TS, et al. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Clinical Oncology. 2017;35(3):361-369. doi:10.1200/JCO.2016.70.7562
Tracy Batchelor, MD, MPH, Helen A Shih, MD. Management of glioblastoma in older adults - UpToDate. :14.
Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. The Lancet Oncology. 2017;18(6):e315-e329. doi:10.1016/S1470-2045(17)30194-8
Wick W. TTFields: where does all the skepticism come from? Neuro-Oncology. 2016;18(3):303-305. doi:10.1093/neuonc/now012
Wick W, Osswald M, Wick A, Winkler F. Treatment of glioblastoma in adults. Therapeutic Advances in Neurological Disorders. 2018;11:175628641879045. doi:10.1177/1756286418790452
Wick W, Platten M. Understanding and Treating Glioblastoma. Neurologic Clinics. 2018;36(3):485-499. doi:10.1016/j.ncl.2018.04.006
Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. 2018 141:467–473. Doi: 10.1007/s11060-018-03057-z
Provided by CAC Members
Chang E, Patel CB, Pohling C, et al. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discovery. 2018;4(1):1-13. doi: 10.1038/s41420-018-0130-x.
Kim EH, Kim YJ, Song HS, et al. Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation. Oncotarget. 2016;7(38):62267-62279. doi: 10.18632/oncotarget.11407.
Kim EH, Song HS, Yoo SH, Yoon M. Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis. Oncotarget. 2016;7(40):65125-65136. doi: 10.18632/oncotarget.11372.
